SIETES :: 92334 citas

Resultados de la búsqueda por DRUG UTILIZATION REFINAR BÚSQUEDA

1.

Park Y, Hernandez-Diaz S, Bateman BT, Cohen JM, Desai RJ, Patorno E, Glynn RJ, Cohen LS, Mogun H, Huybrechts KF. Continuation of atypical antipsychotic medication during early pregnancy and the risk of gestational diabetes. Am J Psychiatry 2018:7 de mayo. [Ref.ID 102604]

2.

Watanabe JH, McInnis T, Hirsch JD. Cost of prescription drug-related morbidity and mortality.. Annals of Pharmacotherapy 2018:26 de marzo. [Ref.ID 102573]

3.

Richardson K, Fox C, Maidment I, Steel N, Loke YK, Arthur A, Myint PK, Grossi CM, Mattishent K, Bennett K, Campbell NL, Boustani M, Robinson L, Brayne C, Matthews FE, Savva GM. Anticholinergic drugs and risk of dementia: case-control study. BMJ 2018;361:25 de abril. [Ref.ID 102571]

4.

Charlton RA, Bettoli V, Bos HJ, Engeland A, Garne E, Gini R, Hansen AV, de Jong-van den Berg LTW, Jordan S, Klungsøyr K, Neville AJ, Pierini A, Puccini A, Sinclair M, Dolk DTH. The limitations of some European healthcare databases for monitoring the effectiveness of pregnancy prevention programmes as risk minimisation measures. Eur J Clin Pharmacol 2018;74:abril. [Ref.ID 102561]

5.

Garattini S, Bertele V. Benefits, benefits, once more benefits... with no risk? Stop overlooking the harms of medicines. Eur J Clin Pharmacol 2018;74:marzo. [Ref.ID 102550]

6.

Peckham AM, Fairman KA, Sclar DA. All-cause and drug-related medical events associated with overuse of gabapentin and/or opioid medications: a retrospective cohort analysis of a commercially insured US population. Drug Saf 2018;41:213-28. [Ref.ID 102542]

7.

Johansen ME. Gabapentinoid use in the United States 2002 rhrough 2015. JAMA Intern Med 2018;178:febrero. [Ref.ID 102530]

8.

Anónimo. Opioid prescriptions fell 10 percent last year, report says . DIA Daily 2018:13. [Ref.ID 102519]

9.

Montastruc F, Bénard-Laribière A, Noize P, Pambrun E, Diaz-Bazin F, Tournier M, Bégaud B, Pariente A. Antipsychotics use: 2006–2013 trends in prevalence and incidence and characterization of users. Eur J Clin Pharmacol 2018;74:mayo. [Ref.ID 102512]

10.

Carey B, Gebeloff R. Many people taking antidepressants discover they cannot quit. N Y Times (Print) 2018:7 de abril. [Ref.ID 102504]

11.

Anónimo. Continued popularity of antipsychotic drug quetiapine highlights problems with off-label use. DIA Daily 2018:6. [Ref.ID 102498]

12.

Wen H, Hockenberry JM. Association of medical and adult-use marijuana laws with opioid prescribing for Medicaid enrollees . JAMA Intern Med 2018:2 de abril. [Ref.ID 102494]

13.

Bradford AC, Bradford WD, Abraham A, Bagwell Adams G. Association between US state medical cannabis laws and opioid prescribing in the Medicare Part D population. JAMA Intern Med 2018:2 de abril. [Ref.ID 102493]

14.

Hill KP, Saxon AJ. The role of cannabis legalization in the opioid crisis. JAMA Intern Med 2018:2 de abril. [Ref.ID 102492]

15.

King LM, Sanchez GV, Bartoces M, Hicks A, Fleming-Dutra KE. Antibiotic Therapy Duration in US Adults With Sinusitis. JAMA Intern Med 2018:26 de marzo. [Ref.ID 102480]

16.

Summerfield D. NHS antidepressant prescribing: what do we get for £266m a year?. BMJ 2018;360:k1019. [Ref.ID 102475]

17.

Pennell PB. Antiepileptic drugs in pregnancy — Quick decisions with long-term consequences. JAMA Neurology 2018:1. [Ref.ID 102464]

18.

Elkjær LS, Bech BH, Sun Y, Laursen TM, Christensen J. Association between prenatal valproate exposure and performance on standardized language and mathematics tests in school-aged children. JAMA Neurology 2018:1. [Ref.ID 102463]

19.

Mir de Francia R. Los fabricantes de opioides fijan a España como nuevo mercado. eldiario.es 2018:1. [Ref.ID 102452]

20.

Johansen ME. Gabapentinoid use in the United States 2002 through 2015. JAMA Intern Med 2018:2 de enero. [Ref.ID 102440]